Waldenstrom's macroglobulinemia in the era of immunotherapy

References

• Bassarova A, Troen G, Spetalen S, et al. Lymphoplasmacytic lymphoma and marginal zone lymphoma in the bone marrow: paratrabecular involvement as an important distinguishing feature. Am J Clin Pathol. 2015;143(6):797–806.
   PubMed Web of Science ®Google Scholar
• Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Sem Oncol. 2003;30(2):110–115.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Larson DR, McPhail ED, et al. Fifty-Year Incidence of Waldenstrom Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. Mayo Clin Proc. 2018;93(6):739–746.
   PubMed Web of Science ®Google Scholar
• Ailawadhi S, Kardosh A, Yang D, et al. Outcome disparities among ethnic subgroups of Waldenstrom's macroglobulinemia: a population-based study. Oncology. 2014;86(5–6):253–262.
   PubMed Web of Science ®Google Scholar
• Buske C, Sadullah S, Kastritis E, et al. Treatment and outcome patterns in European patients with Waldenstrom's macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018;5(7):e299–e309.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Bjorkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood. 2008;112(8):3052–3056.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom's macroglobulinemia. Annals of oncology: official journal of the European Society for. Med Oncol. 2006;17:488–494.
   Google Scholar
• Steingrimsson V, Lund SH, Turesson I, et al. Population-based study on the impact of the familial form of Waldenstrom macroglobulinemia on overall survival. Blood. 2015;125(13):2174–2175.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas C, Hanzis C, et al. Familial disease predisposition impacts treatment outcome in patients with Waldenstrom macroglobulinemia. Clin Lymph Myeloma Leuk. 2012;12(6):433–437.
   PubMed Web of Science ®Google Scholar
• Nipp R, Mitchell A, Pishko A, et al. Waldenstrom macroglobulinemia in hepatitis C: case report and review of the current literature. Oncol Med. 2014;2014:1–7.
   Google Scholar
• Silvestri F, Barillari G, Fanin R, et al. Risk of hepatitis C virus infection, Waldenstrom's macroglobulinemia, and monoclonal gammopathies. Blood. 1996;88(3):1125–1126.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Morel P, Duhamel A, et al. A revised international prognostic score system for Waldenstrom's macroglobulinemia. Leukemia. 2019;33(11):2654–2661.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Olszewski AJ, Kanan S, et al. Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015;169(1):81–89.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Greipp PR, Gertz MA, et al. Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol. 2000;108(4):737–742.
   PubMed Web of Science ®Google Scholar
• Ricci F, Tedeschi A, Montillo M, et al. Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom's Macroglobulinemia. Mediterr J Hematol Infect Dis. 2011;3(1):e2011031.
   PubMedGoogle Scholar
• Castillo JJ, Gertz MA. Secondary malignancies in patients with multiple myeloma, Waldenstrom macroglobulinemia and monoclonal gammopathy of undetermined significance. Leuk Lymph. 2017;58(4):773–780.
   PubMed Web of Science ®Google Scholar
• Varettoni M, Tedeschi A, Arcaini L, et al. Risk of second cancers in Waldenstrom macroglobulinemia. Annal Oncol. 2012;23(2):411–415.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Eloranta S, Dickman PW, et al. Patterns of survival in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. Am J Hematol. 2013;88:60–65.
   PubMed Web of Science ®Google Scholar
• Treon SP. How I treat Waldenstrom macroglobulinemia. Blood. 2009;114(12):2375–2385.
   PubMed Web of Science ®Google Scholar
• Abeykoon JP, Zanwar S, Ansell SM, et al. Predictors of symptomatic hyperviscosity in Waldenstrom macroglobulinemia. Am J Hematol. 2018;93(11):1384–1393.
   PubMed Web of Science ®Google Scholar
• Thomas EL, Olk RJ, Markman M, et al. Irreversible visual loss in Waldenstrom's macroglobulinaemia. Br J Ophthalmol. 1983;67(2):102–106.
   PubMedGoogle Scholar
• Park MS, Kim BC, Kim IK, et al. Cerebral infarction in IgG multiple myeloma with hyperviscosity. J Korean Med Sci. 2005;20(4):699–701.
   PubMed Web of Science ®Google Scholar
• Chae SW, Cho JH, Lee JH, et al. Sudden hearing loss in chronic myelogenous leukaemia implicating the hyperviscosity syndrome. J Laryngol Otol. 2002;116(4):291–293.
   PubMed Web of Science ®Google Scholar
• Cao X, Ye Q, Orlowski RZ, et al. Waldenstrom macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol. 2015;8:74.
   PubMed Web of Science ®Google Scholar
• Baehring JM, Hochberg EP, Raje N, et al. Neurological manifestations of Waldenstrom macroglobulinemia. Nat Rev Neurol. 2008;4(10):547–556.
   Google Scholar
• Baldini L, Nobile-Orazio E, Guffanti A, et al. Peripheral neuropathy in IgM monoclonal gammopathy and Waldenstrom's macroglobulinemia: a frequent complication in elderly males with low MAG-reactive serum monoclonal component. Am J Hematol. 1994;45(1):25–31.
   PubMed Web of Science ®Google Scholar
• Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Data Sys Rev. 2016;10:Cd002827.
   PubMed Web of Science ®Google Scholar
• Gomez A, Hoffman JE. Anti myelin-associated-glycoprotein antibody peripheral neuropathy response to combination chemoimmunotherapy with bendamustine/rituximab in a patient with biclonal IgM kappa and IgM lambda: case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2016;16(7):e101–8.
   PubMed Web of Science ®Google Scholar
• Ueki S, Nakamura M, Sasaki R, et al. Beneficial effect of bendamustine in a patient with anti-MAG/SGPG neuropathy and bing-neel syndrome associated with waldenstrom macroglobulinemia: a case report. Case Rep Neurol. 2018;10(1):88–94.
   PubMed Web of Science ®Google Scholar
• Harel S, Mohr M, Jahn I, et al. Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases. Br J Haematol. 2015;168(5):671–678.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Alexanian R. Waldenstrom's macroglobulinemia. Blood. 1994;83(6):1452–1459.
   PubMed Web of Science ®Google Scholar
• Higgins L, Nasr SH, Said SM, et al. Kidney involvement of patients with waldenstrom macroglobulinemia and other IgM-producing B cell lymphoproliferative disorders. CJASN. 2018;13(7):1037–1046.
   PubMed Web of Science ®Google Scholar
• Leoncini G, Campisi CC, Fraternali Orcioni G, et al. Chylothorax as rare manifestation of pleural involvement in waldenström macroglobulinemia: mechanisms and management. Lymphology. 2016;49(4):210–217.
   PubMed Web of Science ®Google Scholar
• Bartakova H, Novak J, Jaksa R, et al. Endobronchial involvement as an extremely rare manifestation of the Waldenstrom's disease. Clin Respir J. 2018;12(2):816–819.
   PubMed Web of Science ®Google Scholar
• Poisson J, Aregui A, Darnige L, et al. Association of chylothorax and direct pleura involvement in a case of Waldenstrom's macroglobulinaemia. Age Ageing. 2014;43(4):581–583.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Treon SP. How we manage Bing-Neel syndrome. Br J Haematol. 2019;187(3):277–285.
   PubMed Web of Science ®Google Scholar
• Priyanka P, Mercier R, Raiker R, et al. Distal Tibia and Foot Involvement in a Patient With Waldenstrom's Macroglobulinemia. WMJ: official publication of the. State Med Soc Wisconsin. 2018;117(2):88–91.
   Google Scholar
• Knox CM, Wong IG, Howes EL, et al. Vitreitis and Waldenstrom's macroglobulinemia. Am J Ophthalmol. 1998;126(2):314–315.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2006;133(2):158–164.
   PubMed Web of Science ®Google Scholar
• Vos JM, Gustine J, Rennke HG, et al. Renal disease related to Waldenstrom macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol. 2016;175(4):623–630.
   PubMed Web of Science ®Google Scholar
• Audard V, Georges B, Vanhille P, et al. Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum. CJASN. 2008;3(5):1339–1349.
   PubMed Web of Science ®Google Scholar
• Zanwar S, Abeykoon JP, Ansell SM, et al. Primary systemic amyloidosis in patients with Waldenstrom macroglobulinemia. Leukemia. 2019;33(3):790–794.
   PubMed Web of Science ®Google Scholar
• Berentsen S. Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):110–112.
   PubMedGoogle Scholar
• Ciccarelli BT, Patterson CJ, Hunter ZR, et al. Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leukemia. 2011;11(1):160–163.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Ciccarelli BT, et al. Patients with Waldenstrom macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration. Clin Lymphoma Myeloma Leukemia. 2013;13(2):241–243.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A. Waldenstrom's Macroglobulinemia. Best Prac Res Clin Haematol. 2005;18(4):747–765.
   PubMed Web of Science ®Google Scholar
• Side L, Fahie-Wilson MN, Mills MJ. Hypercalcaemia due to calcium binding IgM paraprotein in Waldenstrom's macroglobulinaemia. J Clin Pathol. 1995;48(10):961–962.
   PubMedGoogle Scholar
• Mak WM, Chen PL, Lee K. Misleading hypercalcaemia in a patient with Waldenstrom's macroglobulinaemia. Br J Biomed Sci. 2011;68(4):210–212.
   PubMed Web of Science ®Google Scholar
• Morice WG, Chen D, Kurtin PJ, et al. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenstrom's macroglobulinemia. Modern pathology: an official journal of the United States and Canadian Academy of Pathology. Mod Pathol. 2009;22(6):807–816.
   PubMed Web of Science ®Google Scholar
• Tournilhac O, Santos DD, Xu L, et al. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Annal Oncol. 2006;17(8):1275–1282.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi C, Trieu Y, et al. Prognostic relevance of 6q deletion in Waldenstrom's macroglobulinemia: a multicenter study. Clin Lymphoma Myeloma. 2009;9(1):36–38.
   PubMedGoogle Scholar
• Nguyen-Khac F, Lambert J, Chapiro E, on behalf of the Groupe Francais d'Etude de la Leucemie Lymphoide Chronique et Maladie de WaldenstromGroupe Francais d'Etude (GFCLL/MW) Sang Groupe Ouest-Est d'etude des Leucemie Aigues et Autres Maladies du and de l'Adulte (GOELAMS) Groupe d'Etude des Ly, et al. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom's macroglobulinemia. Haematologica. 2013;98(4):649–654.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi X, Xu W, et al. Analysis of 6q deletion in Waldenstrom macroglobulinemia. Eur J Haematol. 2007;79(3):244–247.
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med. 2012;367(9):826–833.
   PubMed Web of Science ®Google Scholar
• Treon SP, Gustine J, Xu L, et al. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018;180(3):374–380.
   PubMed Web of Science ®Google Scholar
• Abeykoon JP, Paludo J, King RL, et al. MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia. Am J Hematol. 2018;93(2):187–194.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Moreno DF, Arbelaez MI, et al. CXCR4 mutations affect presentation and outcomes in patients with Waldenstrom macroglobulinemia: a systematic review. Exper Rev Hematol. 2019;12(10):873–881.
   PubMed Web of Science ®Google Scholar
• Varettoni M, Zibellini S, Defrancesco I, et al. Pattern of somatic mutations in patients with Waldenstrom macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica. 2017;102(12):2077–2085.
   PubMed Web of Science ®Google Scholar
• Martinez-Lopez A, Curiel-Olmo S, Mollejo M, et al. MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma. Am J Surg Pathol. 2015;39(5):644–651.
   PubMed Web of Science ®Google Scholar
• Behdad A, Zhou XY, Gao J, et al. High frequency of MYD88 L265P mutation in primary ocular adnexal marginal zone lymphoma and its clinicopathologic correlation: a study from a single institution. Arch Pathol Lab Med. 2019;143(4):483–493.
   PubMed Web of Science ®Google Scholar
• Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med. 2012;367(23):2255–2256.
   PubMed Web of Science ®Google Scholar
• Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11):2051–2058.
   PubMed Web of Science ®Google Scholar
• Correa JG, Cibeira MT, Tovar N, et al. Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenstrom macroglobulinaemia. Br J Haematol. 2017;179(5):849–851.
   PubMed Web of Science ®Google Scholar
• Pophali PA, Bartley A, Kapoor P, et al. Prevalence and survival of smouldering Waldenstrom macroglobulinaemia in the United States. Br J Haematol. 2019;184(6):1014–1017.
   PubMed Web of Science ®Google Scholar
• Willenbacher W, Willenbacher E, Brunner A, et al. Improved accuracy of discrimination between IgM multiple myeloma and Waldenstrom macroglobulinaemia by testing for MYD88 L265P mutations. Br J Haematol. 2013;161(6):902–904.
   PubMed Web of Science ®Google Scholar
• Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, et al. Progression risk stratification of asymptomatic Waldenstrom Macroglobulinemia. J Clin Oncol. 2019;37(16):1403–1411.
   PubMed Web of Science ®Google Scholar
• Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163–4170.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Kyrtsonis MC, Hadjiharissi E, et al. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leukemia Res. 2010;34(10):1340–1343.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Delimpassi S, et al. The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens. Haematologica. 2008;93(9):1420–1422.
   PubMed Web of Science ®Google Scholar
• Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160(2):171–176.
   PubMed Web of Science ®Google Scholar
• Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenstrom's Macroglobulinemia. Blood. 2016;128(10):1321–1328.
   PubMed Web of Science ®Google Scholar
• Stone MJ, Bogen SA. Role of plasmapheresis in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013;13(2):238–240.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Acute hyperviscosity: syndromes and management. Blood. 2018;132(13):1379–1385.
   PubMed Web of Science ®Google Scholar
• Miyamoto Y, Hamasaki Y, Matsumoto A, et al. Prediction of immunoglobulin M reduction via therapeutic dose of simple plasma exchange and double filtration plasmapheresis using membrane separation in patients with hyperviscosity syndrome caused by Waldenstrom macroglobulinemia. J Clin Apher. 2018;33(5):611–615.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004;45(10):2047–2055.
   PubMed Web of Science ®Google Scholar
• Santos-Lozano A, Morales-Gonzalez A, Sanchis-Gomar F, et al. Response rate to the treatment of Waldenstrom macroglobulinemia: A meta-analysis of the results of clinical trials. Crit Rev Oncol Hematol. 2016;105:118–126.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Alexanian R, Gika D, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression. Leuk Lymphoma. 2004;45(10):2057–2061.
   PubMed Web of Science ®Google Scholar
• Treon SP, Yang G, Hanzis C, et al. Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia. Br J Haematol. 2011;154(2):223–228.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004;101(11):2593–2598.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Meid K, Gustine JN, et al. Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenstrom Macroglobulinemia. Clin Cancer Res. 2018;24(14):3247–3252.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122(19):3276–3282.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Lerchenmüller C, Hensel M, et al. Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial). Blood. 2019;134:343.
   Web of Science ®Google Scholar
• Treon SP, Hanzis C, Manning RJ, et al. Maintenance Rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol. 2011;154(3):357–362.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Gustine JN, Meid K, et al. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstrom macroglobulinaemia. Br J Haematol. 2018;181(1):77–85.
   PubMed Web of Science ®Google Scholar
• Saurabh Zanwar JPA, Gertz MA, Kumar S, et al. Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study. J Clin Oncol. 37:7559.
   Web of Science ®Google Scholar
• Grisariu S, Vaxman I, Gatt M, et al. Enteroviral infection in patients treated with rituximab for non-Hodgkin lymphoma: a case series and review of the literature. Hematol Oncol. 2017;35(4):591–598.
   PubMed Web of Science ®Google Scholar
• Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine. 2010;89(5):308–318.
   PubMed Web of Science ®Google Scholar
• Furman RR, Eradat HA, DiRienzo CG, et al. Once-weekly ofatumumab in untreated or relapsed Waldenstrom's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017;4(1):e24–e34.
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Kastritis E, Kyrtsonis MC, et al. Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenstrom's macroglobulinemia. Leuk Lymphoma. 2017;58(6):1506–1508.
   PubMed Web of Science ®Google Scholar
• Salles G, Morschhauser F, Lamy T, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012;119(22):5126–5132.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Gavriatopoulou M, Kyrtsonis MC, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study. Blood. 2015;126(11):1392–1394.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25(22):3344–3349.
   PubMed Web of Science ®Google Scholar
• Laribi K, Poulain S, Willems L, et al. Bendamustine plus rituximab in newly-diagnosed Waldenstrom macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol. 2019;186(1):146–149.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011;11(1):133–135.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
   PubMed Web of Science ®Google Scholar
• Martin P, Chen Z, Cheson BD, et al. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. Br J Haematol. 2017;178(2):250–256.
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Boumendil A, Finel H, et al. Autologous Stem Cell Transplantation (ASCT) for the Treatment of Patients with Waldenstrom’s Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL). A risk factor analysis by the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party. Blood. 2014;124:678.
   PubMed Web of Science ®Google Scholar
• Saini NY, Patel RD, Varma A, et al. Outcomes of autologous stem cell transplantation in Waldenstrom's macroglobulinemia. Ann Hematol. 2019;98(9):2233–2235.
   PubMed Web of Science ®Google Scholar
• Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27(23):3830–3835.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia. Am J Hematol. 2010;85(9):670–674.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter ZR, Matous J, Joyce RM, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res. 2007;13(11):3320–3325.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28(8):1422–1428.
   PubMed Web of Science ®Google Scholar
• Strauss SJ, Maharaj L, Hoare S, Johnson PW, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol. 2006;24(13):2105–2112.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia. Blood. 2014;124(4):503–510.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med. 2015;372(15):1430–1440.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia. N Engl J Med. 2018;378(25):2399–2410.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18(2):241–250.
   PubMed Web of Science ®Google Scholar
• Buske CT, Trotman J. Ibrutinib treatment in Waldenström’s Macroglobulinemia: follow-up efficacy and safety from the iNNOVATETM study. San-diego: ASH; 2018.
   Google Scholar
• Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom Macroglobulinemia. J Clin Oncol. 2018;36(27):2755–2761.
   PubMed Web of Science ®Google Scholar
• Abeykoon JP, Zanwar S, Ansell SM, et al. Ibrutinib monotherapy outside of clinical trial setting in Waldenstrom macroglobulinaemia: practice patterns, toxicities and outcomes. Br J Haematol. 2019.
   PubMed Web of Science ®Google Scholar
• Owen R, McCarthy H, Rule S, et al. Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM). J Clin Oncol. 2018;36:7501.
   Web of Science ®Google Scholar
• Dimopoulos M, Opat S, Lee H-P, et al. Major responses in myd88 wildtype (MYD88WT) Waldenström macroglobulinemia (WM) patients treated with bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111). EHA Library. 2019; 266287:PF487.
   Google Scholar
• Munakata W, Sekiguchi N, Shinya R, et al. Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor. Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia. Blood. 2019;134:345.
   Web of Science ®Google Scholar
• Paulus A, Akhtar S, Yousaf H, et al. Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J. 2017;7(5):e565–e565.
   PubMedGoogle Scholar
• Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–833.
   PubMed Web of Science ®Google Scholar
• Castillo J, Allan J, Siddiqi T, et al. Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2019;19:e39–e40.
   Web of Science ®Google Scholar